Syngene International, one of Asia’s largest R&D focused contract research organization, has now set up an integrated, multi-disciplinary drug discovery and development center for Amgen, Inc. This is the fourth dedicated research centre in Bengaluru for global pharma companies, the earlier ones for Bristol-Myers Squibb, Abbott Nutrition and Baxter Inc.

The new centre Syngene Amgen Research and Development Center (SARC), is an advanced facility. It will be staffed by a team of over 100 highly qualified Syngene scientists, working in close association with Amgen researchers globally on the discovery and development of innovative medicines.

In addition to being customized to meet Amgen's functional requirements, the facility complies with the highest regulatory standards. Its design includes a range of environmentally-friendly features and flexible layouts, and is configured to minimize solvent and effluent waste with a strong emphasis on laboratory safety and ‘green’ chemistry.  

Syngene has partnered with Amgen in a variety of discovery and development projects. With the establishment of SARC, this association now extends into a multi-discipline collaboration spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharmaceutical development.

"We are delighted to announce the establishment of our dedicated R&D center for Amgen. Bringing together into one place, the range of activities we conduct on behalf of Amgen indicates the strategic nature of our relationship and also reflects the ability of the company’s scientific teams to deliver world-class science towards our partners’ R&D programs in both biotechnology and small molecule medicines, said Jonathan Hunt, chief executive officer, Syngene International.